TABLE 1.

Anti-cancer drugs for potential combination therapy with CX-4945 in treatment of human hematological cancers.

Disease	Target CK2 subunits	Combined inhibitors	Target	IC50 or Ki	Reference
CLL	α, α′	Ibrutinib	BTK (Bruton’s tyrosine kinase)	0.5 nM (Ki)	Honigberg et al. (2010)
ALL	α, α′	Temsirolimus	mTOR	1.76 μM	Shor et al. (2008)
CML	α, β	Imatinib	Bcr-Abl	0.6 μM	Buchdunger et al. (1995)
AML	α, β	Daunorubicin	DNA or RNA synthesis	0.02 μM	Gewirtz (1999)
MM	α, β	Bortezomib	20S proteasome	0.6 nM (Ki)	Adams et al. (1999)